


Maintenance therapy for patients not eligible for transplant

In general, for patients with MM who are not eligible for transplant and are receiving lenalidomide- or bortezomib-based therapy, at what point do you initiate maintenance therapy?



EDITOR'S COMMENTS

Almost all oncologists administer maintenance treatment for elderly patients, usually (as with the faculty) after maximal response is observed. The FIRST trial used two approaches to Rd, one for a fixed duration of 18 cycles and the other indefinitely, which was the randomization arm with the best results. Dr Vij treats indefinitely, but for older patients receiving bortezomib he generally limits maintenance to 1 year, particularly because of the inconvenience of parenteral administration. Dr Munshi notes that the recent emergence of oral proteasome inhibitors such as ixazomib and oprozomib may dramatically alter the landscape for proteasome maintenance therapy in the future.

SELECT REFERENCES WITH LINKS

McCarthy P et al. **Lenalidomide after stem-cell transplantation for multiple myeloma.** *N Engl J Med* 2012;366(19):1770-81. [Abstract](#)

Palumbo A et al. **Continuous lenalidomide treatment for newly diagnosed multiple myeloma.** *N Engl J Med* 2012;366(19):1759-69. [Abstract](#)

Benboubker L et al. **Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.** *N Engl J Med* 2014;371(10):906-17. [Abstract](#)